By Josh Beckerman
Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.
The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.
Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.
The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
April 16, 2025 14:39 ET (18:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.